Intestinal microbiota and faecal transplantation as treatment modality for insulin resistance and type 2 diabetes mellitus
Author(s) -
Udayappan S. D.,
Hartstra A. V.,
DallingaThie G. M.,
Nieuwdorp M.
Publication year - 2014
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/cei.12293
Subject(s) - insulin resistance , transplantation , biology , type 2 diabetes mellitus , gut flora , immunology , obesity , inflammation , disease , diabetes mellitus , fecal bacteriotherapy , medicine , endocrinology , microbiology and biotechnology , antibiotics , clostridium difficile
Summary The prevalence of obesity and diabetes mellitus type 2 is increasing rapidly around the globe. Recent insights have generated an entirely new perspective that the intestinal microbiota may play a significant role in the development of these metabolic disorders. Alterations in the intestinal microbiota composition promote systemic inflammation that is a hallmark of obesity and subsequent insulin resistance. Thus, it is important to understand the reciprocal relationship between intestinal microbiota composition and metabolic health in order to eventually prevent disease progression. In this respect, faecal transplantation studies have implicated that butyrate‐producing intestinal bacteria are crucial in this process and be considered as key players in regulating diverse signalling cascades associated with human glucose and lipid metabolism.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom